MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo

International Journal of Cancer. Journal International Du Cancer
Vladimir KirkinJonathan P Sleeman

Abstract

We have recently described MAZ51, an indolinone that blocks the ligand-induced autophosphorylation of VEGFR-3, a receptor tyrosine kinase that plays a central role in the regulation of lymphangiogenesis. Here we show that MAZ51 is able to block the proliferation of VEGFR-3-expressing human endothelial cells and is less potently able to induce their apoptosis. MAZ51 also inhibits the proliferation and induces the apoptosis of a variety of non-VEGFR-3-expressing tumor cell lines. These data suggest that MAZ51 blocks the activity of tyrosine kinases in addition to VEGFR-3. In vivo, MAZ51 significantly inhibits the growth of rat mammary carcinomas. These data establish MAZ51 as a compound with antitumor properties that inhibits tumor growth directly and also indirectly by interfering with tumor-host interactions.

References

Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·B WestermarkL Claesson-Welsh
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·A KaipainenK Alitalo
Jan 1, 1994·Urology·H MatzkinM S Soloway
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·J LeeW I Wood
May 30, 1997·Science·M JeltschK Alitalo
Jul 31, 1997·Oncogene·L J FitzC R Wood
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G AchenS A Stacker
Jun 17, 2000·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·J P Sleeman
Feb 15, 2001·Nature Medicine·S A StackerM G Achen
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Mirjami M-T MattilaPirkko L Härkönen
Jun 28, 2002·Cancer Cell·Laura K ShawverAxel Ullrich
Jun 28, 2002·Physiological Reviews·Lotta Jussila, Kari Alitalo
Jul 18, 2002·Nature Reviews. Drug Discovery·Margaret A Somerville
Dec 10, 2002·Science·G ManningS Sudarsanam
Jan 8, 2003·Seminars in Oncology·Judah Folkman
Feb 26, 2004·Journal of Immunological Methods·Herbert A WeichJonathan Sleeman
Feb 27, 2004·Biochimica Et Biophysica Acta·Yulong HeKari Alitalo

❮ Previous
Next ❯

Citations

Dec 20, 2008·Lymphatic Research and Biology·Steven A Stacker, Marc G Achen
Oct 3, 2012·PloS One·Scott J HoffmanRobert D Simari
Feb 19, 2010·Folia Histochemica Et Cytobiologica·Bozena WeryńskaRenata Jankowska
Jun 28, 2011·Advanced Drug Delivery Reviews·Jennifer D McAllaster, Mark S Cohen
Mar 28, 2009·International Journal of Cancer. Journal International Du Cancer·Melanie RothleyJonathan P Sleeman
Apr 12, 2011·Journal of Surgical Oncology·Marlys H WitteJeffrey E Gershenwald
Feb 25, 2006·Journal of Biotechnology·Wilko Thiele, Jonathan P Sleeman
Jun 17, 2015·Survey of Ophthalmology·Nariman NassiriRobert A Goldberg
Aug 11, 2016·Biochemical and Biophysical Research Communications·Ji Yoon LeeIn Ho Jang
May 9, 2009·Circulation Research·Hajime FukuiAtsuo Kawahara
Sep 19, 2019·Laboratory Animals·Wilko ThieleJonathan P Sleeman
Apr 3, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Jerome W BreslinMack H Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis